Skip to main content

AMIA’s goal is to improve the legislative and regulatory environment for health informatics research, practice and education through AMIA member expertise.  The primary pathway through which AMIA achieves this goal is by engaging Federal Agencies and Congress on public calls for input, such as Notices of Proposed Rulemakings (NPRMs) or Request for Information (RFIs).

Learn more about the comment process

AMIA responses are arranged by Federal Agency and Congressional Committee.

Showing 41 - 50 out of 98

AMIA Applauds Flexibilities, Supports 2015 CEHRT Timeline in IPPS Proposed Rule

June 13, 2017

In comments to CMS, AMIA supported proposals to reduce the number of required quality measures and new proposed reporting period flexibilities, while also recommending additional such flexibilities for the 2018 Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs. AMIA additionally agreed with the proposed rule’s analysis that […]

AMIA Response to NLM Strategic Plan

January 31, 2017

In comments submitted to the National Library of Medicine, AMIA said members envision a future where NLM leads the medical and research enterprise in demonstrating how real-world and “big” health data can be leveraged to develop new concepts of human disease, design novel therapies, and train future clinicians and researchers.

AMIA Response to PCORI Data Sharing Plan

January 24, 2017

In comments submitted to PCORI, AMIA voiced strong support for its draft Data Sharing Policy for awardees.  AMIA recommended that suggested that PCORI consider requiring a preliminary data sharing plan as part of award applications, and earmarking specified amounts of grant funding for data preparation and curation, among other recommendations.

AMIA Comments Regarding FDA’s Medical Device User Fee Agreement Letter (MDUFA IV)

November 2, 2016

In comments submitted to the FDA, AMIA voiced supported for several aspects of MDUFA IV meant to enhance use of consensus standards; develop patient engagement strategies and improve the science of patient input; utilize real world evidence (RWE) to improve regulatory decision-making; and development of a policy framework for Digital […]

AMIA Response to FDA Draft Guidance on the Use of Public Human Genetic Variant Databases to Support Clinical Validity for Next Generation Sequencing (NGS)-Based In Vitro Diagnostics

October 6, 2016

In comments submitted to the FDA, AMIA said it supports FDA’s efforts to develop modern, flexible and adaptive regulatory approaches to the oversight of NGS-based tests as part of the Precision Medicine Initiative (PMI).  This support notwithstanding, AMIA noted a lack of standards – for ontologies, metadata and other technical […]

AMIA Response to NIH RFI on Metrics to Assess Value of Biomedical Digital Repositories

October 5, 2016

In comments submitted September 29, AMIA recommend several ways the NIH could assess the value of biomedical digital repositories and knowledgebases.  The metrics span categories related to "utilization" and "impact" to "service quality" and "governance."  AMIA recommended another category be included relate to data quality and data completeness.

AMIA Comments Regarding FDA PDUFA VI Commitment Letter

August 16, 2016

In conjunction with a public meeting held by the FDA August 15, 2016, AMIA submitted public comments supporting the direction of the its Prescription Drug User Fee Agreement Commitment Letter.  Specifically, AMIA supports FDA’s work to utilize Real World Evidence in regulatory decision-making, incorporating the patient’s voice in drug development […]